Source 1primary paper2025MED
Toolkit/GVs-HV recombinant plasmid
GVs-HV recombinant plasmid
Also known as: Hirudin-Gas Vesicle Recombinant Plasmid
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
In this work, we constructed a Hirudin-Gas Vesicle Recombinant Plasmid to achieve gene delivery using macrophage membrane/lipid membrane fusion bio-vesicles.
Usefulness & Problems
Why this is useful
This recombinant plasmid is presented as a combined hirudin-gas vesicle gene-delivery construct for anti-atherosclerosis therapy. The abstract states that it can escape lysosomes, enter the nucleus, and support highly efficient transfection.; gene delivery of combined hirudin and gas vesicle functions; ultrasound-assisted anti-atherosclerosis therapy
Source:
This recombinant plasmid is presented as a combined hirudin-gas vesicle gene-delivery construct for anti-atherosclerosis therapy. The abstract states that it can escape lysosomes, enter the nucleus, and support highly efficient transfection.
Source:
gene delivery of combined hirudin and gas vesicle functions
Source:
ultrasound-assisted anti-atherosclerosis therapy
Problem solved
It is intended to couple plaque-disrupting ultrasound-responsive gas vesicles with hirudin-mediated fragment ablation, anti-inflammatory activity, and lipid regulation in one system.; combines complementary therapeutic functions in one recombinant plasmid
Source:
It is intended to couple plaque-disrupting ultrasound-responsive gas vesicles with hirudin-mediated fragment ablation, anti-inflammatory activity, and lipid regulation in one system.
Source:
combines complementary therapeutic functions in one recombinant plasmid
Problem links
combines complementary therapeutic functions in one recombinant plasmid
LiteratureIt is intended to couple plaque-disrupting ultrasound-responsive gas vesicles with hirudin-mediated fragment ablation, anti-inflammatory activity, and lipid regulation in one system.
Source:
It is intended to couple plaque-disrupting ultrasound-responsive gas vesicles with hirudin-mediated fragment ablation, anti-inflammatory activity, and lipid regulation in one system.
Published Workflows
Objective: Engineer and evaluate a macrophage-membrane-fused liposomal gene-delivery system carrying a Hirudin-Gas Vesicle recombinant plasmid for targeted anti-atherosclerosis therapy, including ultrasound-assisted plaque treatment.
Why it works: The abstract presents a complementary mechanism in which macrophage-membrane proteins support lesion targeting, the plasmid achieves intracellular delivery and transfection, and the encoded hirudin and gas vesicle functions jointly support plaque disruption and anti-inflammatory therapy.
integrin α4β21-mediated inflammatory vascular targetinglysosomal escape and nuclear entry of delivered plasmidultrasound-triggered gas vesicle cavitation for plaque disruptionhirudin-mediated fragment ablation, anti-inflammatory activity, and lipid regulationrecombinant plasmid constructionmacrophage membrane/lipid membrane fusion vesicle deliveryultrasound-assisted therapy
Stages
- 1.Recombinant plasmid construction(library_build)
To create the therapeutic genetic payload used in the delivery system.
Selection: Construction of a Hirudin-Gas Vesicle recombinant plasmid for gene delivery.
- 2.Biomimetic delivery system assembly and targeting feature retention(functional_characterization)
To provide lesion-targeting delivery of the recombinant plasmid.
Selection: Use macrophage membrane/lipid membrane fusion bio-vesicles retaining integrin α4β21 for inflammatory vascular delivery.
- 3.Intracellular trafficking and transfection characterization(secondary_characterization)
To verify that the delivered plasmid can reach the nucleus and function after targeted delivery.
Selection: Assess lysosomal escape, nuclear entry, and highly efficient transfection.
- 4.Ultrasound-assisted mechanistic testing(confirmatory_validation)
To confirm the mechanistic contribution of gas vesicles under ultrasound.
Selection: Test whether gas vesicles can break up lesion plaques with in vitro ultrasound.
- 5.Mouse therapeutic evaluation(in_vivo_validation)
To test whether the engineered system produces therapeutic benefit in an animal atherosclerosis context.
Selection: Evaluate plaque regression, anti-inflammatory effects, safety, and hemodynamic improvement in mice.
Steps
- 1.Construct Hirudin-Gas Vesicle recombinant plasmidengineered therapeutic genetic payload
Create the combined hirudin and gas vesicle plasmid used for gene delivery.
The therapeutic payload must be built before it can be loaded into the delivery vesicles.
- 2.Deliver plasmid using macrophage membrane/lipid membrane fusion bio-vesiclespayload and delivery harness
Enable targeted delivery of the recombinant plasmid to inflammatory vascular lesions.
Targeted delivery is needed before intracellular trafficking and therapeutic action can be evaluated.
- 3.Assess lysosomal escape, nuclear entry, and transfectiondelivered plasmid under test
Verify that the delivered plasmid reaches the nucleus and supports efficient transfection.
Intracellular trafficking must be confirmed after delivery and before attributing downstream therapeutic effects to the construct.
- 4.Apply in vitro ultrasound to test gas-vesicle-mediated plaque breakupultrasound-responsive therapeutic component
Confirm that gas vesicles contribute plaque-disruption activity under ultrasound.
This mechanistic test links the gas-vesicle component to the intended ultrasound-assisted therapeutic effect before or alongside in vivo efficacy interpretation.
- 5.Compare liposomal and macrophage-membrane-fused formulations in mice, including ultrasound-assisted treatmenttherapeutic formulations under comparison
Evaluate in vivo plaque regression, anti-inflammatory effects, safety, and hemodynamic outcomes.
Animal testing is used as the higher-fidelity validation stage after mechanistic and delivery rationale are established.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
lysosomal escapenuclear entrytargeted adhesion via integrin α4β21 binding to vascular adhesion moleculesultrasound-responsive plaque disruptionTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
The construct is delivered using macrophage membrane/lipid membrane fusion bio-vesicles. Ultrasound is used to assist the gas-vesicle-mediated plaque-disruption effect.; requires delivery by macrophage membrane/lipid membrane fusion bio-vesicles; ultrasound assistance is part of the reported gas-vesicle therapeutic effect
The abstract does not show that the plasmid alone is sufficient without the vesicle delivery system or ultrasound assistance. It also does not provide detailed sequence or architecture information.; precise plasmid architecture is not described in the abstract
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The Hirudin-Gas Vesicle recombinant plasmid could escape lysosomes and enter the nucleus to achieve highly efficient transfection.
GVs-HV@Lipo reduced mice aortic arch plaque area by 17%, and GVs-HV@MM-Lipo plus ultrasound achieved further plaque regression and improved hemodynamics.
aortic arch plaque area reduction 17 %
The study constructed a Hirudin-Gas Vesicle recombinant plasmid for gene delivery using macrophage membrane/lipid membrane fusion bio-vesicles.
Gas vesicles can break up lesion plaques with in vitro ultrasound, while hirudin mediates fragment ablation and anti-inflammatory and lipid-regulatory effects.
The bio-fusion vesicles retained macrophage membrane protein integrin α4β21 to bind vascular adhesion molecules highly expressed by inflammatory cells and achieve delivery.
GVs-HV@MM-Lipo exerts potent anti-atherosclerotic and anti-inflammatory effects with favorable safety.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug gvs-hv-recombinant-plasmid
In this work, we constructed a Hirudin-Gas Vesicle Recombinant Plasmid to achieve gene delivery using macrophage membrane/lipid membrane fusion bio-vesicles.
Source:
cellular traffickingsupports
The Hirudin-Gas Vesicle recombinant plasmid could escape lysosomes and enter the nucleus to achieve highly efficient transfection.
Source:
constructionsupports
The study constructed a Hirudin-Gas Vesicle recombinant plasmid for gene delivery using macrophage membrane/lipid membrane fusion bio-vesicles.
Source:
mechanism of actionsupports
Gas vesicles can break up lesion plaques with in vitro ultrasound, while hirudin mediates fragment ablation and anti-inflammatory and lipid-regulatory effects.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts macrophage-membrane-fused liposomal delivery with a liposome-only formulation, GVs-HV@Lipo.
Source:
The abstract contrasts macrophage-membrane-fused liposomal delivery with a liposome-only formulation, GVs-HV@Lipo.
Source-backed strengths
reported to escape lysosomes and enter the nucleus for highly efficient transfection; supports linked and complementary pharmacological effects of hirudin and gas vesicles
Source:
reported to escape lysosomes and enter the nucleus for highly efficient transfection
Source:
supports linked and complementary pharmacological effects of hirudin and gas vesicles
Ranked Citations
- 1.